Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)
First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for...
Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics
PHILADELPHIA, May 2, 2025 /PRNewswire/ -- Darnatein, a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will present scientific data at the 14th International Bone...
S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial
SEOUL, South Korea, May 1, 2025 /PRNewswire/ -- S&E bio Co., Ltd., a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate a Phase 1b...
YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia
SHANGHAI, April 28, 2025 /PRNewswire/ -- YolTech Therapeutics Co.,Ltd, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, announced promising interim clinical data from an...
Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology
SEOUL, South Korea, April 9, 2025 /PRNewswire/ -- Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional international patent for its protein-based osteoarthritis...
Accropeutics Secured $12 Million in Series B Plus Financing
Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST). Cash...
Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases,...
Accropeutics Inc. Announces U.S. FDA Clearance of IND Application for RIPK2 Inhibitor AC-101
Company to conduct a Phase II multi-regional clinical trial (MRCT) for the treatment of Ulcerative Colitis (UC) A Phase Ib Study of AC-101 for Ulcerative Colitis (UC) has been initiated in China AC-101 demonstrated a favorable safety and PK/PD...
THE GLEN GRANT DEVOTION 70-YEAR-OLD SELLS FOR £81,250 ($101,300 USD) AT AUCTION WITH PROCEEDS TO BENEFIT THE ROYAL SCOTTISH FORESTRY SOCIETY
Sotheby's has completed the sale of the first of the seven total decanters, each one-of-a-kind, and housing an exquisite 70-year-old single malt whisky, the oldest release from The Glen Grant distillery. ROTHES, Scotland, Sept. 26, 2023 /PRNewswire/...
US FDA Grants Orphan Drug Designation of SN Bioscience's Nano Anti-Cancer Drug 'SNB-101' for Small Cell Lung Cancer
SEONGNAM, South Korea, July 21, 2023 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on July 19 that the US FDA had granted an orphan drug designation for small cell lung cancer for SNB-101 (API: SN-38), a new polymer...